Roche begins Phase 2 obesity trial for GLP-1/GIP agonist, striking while iron is hot
Roche said it would step on the gas pedal to catch up to Novo Nordisk and Eli Lilly (plus many other hopefuls) in obesity. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
